Illumina, Inc. (ILMN)
Builds machines and supplies that read and analyze DNA sequences for research and medical testing.
$189.93+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+101.0%
The outlook
Illumina is trading near the top of its 52-week range, well above its key moving averages, reflecting strong recent momentum. Analyst consensus leans toward buying, though the average price target sits about 9% below current levels, suggesting some caution. The stock carries a relatively high trailing P/E of 34.6, which reflects investor expectations already priced in.
What’s behind the score
Analyst consensusBuy — 2.4 avg of 19 analysts
Price trendAbove its 50- & 200-day averages
52-week range92% of the way from its 52-week low to high
Price targetAvg target -9% vs current price
Analyst price target
~12-month · 19 analysts$172.53average target-9.2% vs now
Now $189.93
Low $95.00High $220.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$28.74B
52-wk high
$199.14
52-wk low
$88.00
50-day avg
$170.84
200-day avg
$137.61
Trailing P/E
34.6